Adjuvant Chemotherapy for Adult Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial

Author:

Frustaci Sergio1,Gherlinzoni Franco1,De Paoli Antonino1,Bonetti Marco1,Azzarelli Alberto1,Comandone Alessandro1,Olmi Patrizia1,Buonadonna Angela1,Pignatti Giovanni1,Barbieri Enza1,Apice Gaetano1,Zmerly Hassan1,Serraino Diego1,Picci Piero1

Affiliation:

1. From the Unità Operativa di Oncologia Medica and di Oncologia Radioterapica and the Servizio di Epidemiologia, Centro di Riferimento Oncologico, Aviano; and Unità Operativa di Ortopedia, Ospedale Civile, Gorizia; and Unità Operativa di Chirurgia Muscolo-Scheletrica, Istituto Nazionale Tumori, Milano; and Unità Operativa di Oncologia Medica, Ospedale di Gradenigo, Torino; and Divisione di Radioterapia, Università di Firenze; and V Divisione and Laboratorio di Ricerca Oncologica, Istituti Ortopedici...

Abstract

PURPOSE: Adjuvant chemotherapy for soft tissue sarcoma is controversial because previous trials reported conflicting results. The present study was designed with restricted selection criteria and high dose-intensities of the two most active chemotherapeutic agents. PATIENTS AND METHODS: Patients between 18 and 65 years of age with grade 3 to 4 spindle-cell sarcomas (primary diameter ≥ 5 cm or any size recurrent tumor) in extremities or girdles were eligible. Stratification was by primary versus recurrent tumors and by tumor diameter greater than or equal to 10 cm versus less than 10 cm. One hundred four patients were randomized, 51 to the control group and 53 to the treatment group (five cycles of 4′-epidoxorubicin 60 mg/m2 days 1 and 2 and ifosfamide 1.8 g/m2 days 1 through 5, with hydration, mesna, and granulocyte colony-stimulating factor). RESULTS: After a median follow-up of 59 months, 60 patients had relapsed and 48 died (28 and 20 in the treatment arm and 32 and 28 in the control arm, respectively). The median disease-free survival (DFS) was 48 months in the treatment group and 16 months in the control group (P = .04); and the median overall survival (OS) was 75 months for treated and 46 months for untreated patients (P = .03). For OS, the absolute benefit deriving from chemotherapy was 13% at 2 years and increased to 19% at 4 years (P = .04). CONCLUSION: Intensified adjuvant chemotherapy had a positive impact on the DFS and OS of patients with high-risk extremity soft tissue sarcomas at a median follow-up of 59 months. Therefore, our data favor an intensified treatment in similar cases. Although cure is still difficult to achieve, a significant delay in death is worthwhile, also considering the short duration of treatment and the absence of toxic deaths.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Reference27 articles.

1. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma.

2. Tumors of the connective and supporting tissues

3. Spiro IJ, Gebhardt MC, Candace Jennings L, et al: Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery. Semin Oncol 24: 540,1997-546,

4. Future directions in the management of soft tissue sarcomas

5. Frustaci S, Gherlinzoni F, De Paoli A, et al: Preliminary results of an adjuvant randomized trial on high risk extremity soft tissue sarcomas (STS): The interim analysis. Proc Am Soc Clin Oncol 16: 496a,1997 (abstr)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3